The effect of eszopiclone 3 mg compared to placebo on daytime function in subjects with insomnia related to rheumatoid arthritis

Trial Profile

The effect of eszopiclone 3 mg compared to placebo on daytime function in subjects with insomnia related to rheumatoid arthritis

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Oct 2006

At a glance

  • Drugs Eszopiclone (Primary)
  • Indications Insomnia
  • Focus Pharmacodynamics
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 12 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top